Ann: Deferral of Proposed USA Medicare Changes, page-8

If the market was valuing this correctly it would already be well above that price. Unfortunately there just aren't enough "eyes" on EYE yet. Of course, that will change when the audited results are released showing continued solid revenue growth and positive EBITDA, as the market will be unable to ignore the hard numbers, but until then I am guessing we will need to be patient. Of course, that could all change if the company increases communication with the market, a fundie notices this stock and starts to load up, and of course if a 2RT deal is secured soon. I guess this presents an opportunity for investors to continue to accumulate at incredibly low prices, but like everyone here I'm definitely keen to finally see EYE rerate to its fair value.